Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 0899 • ACR Convergence 2020
Secukinumab Provides Significant Improvement of Spinal Pain and Lowers Disease Activity in Patients with Axial Spondyloarthritis: 24-week Results from a Randomized Controlled Phase 3b Trial
Denis Poddubnyy¹, Effie Pournara², Agnieszka Zielinska³, Asta Baranauskaite⁴, Alejandro Muñoz Jiménez⁵, Sanchayita Sadhu⁶, Barbara Schulz², Michael Rissler², Chiara Perella² and Helena Marzo-Ortega⁷, ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³Medycyna Kliniczna, Warszawa, Poland, ⁴Lithuanian University of Health Sciences, Kaunas, Lithuania, ⁵H. U. Virgen del Rocío (Sevilla), Sevilla, Spain, ⁶Novartis Healthcare Private Limited, Hyderabad, Telangana, India, ⁷The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: SKIPPAIN (NCT03136861) is the first randomized controlled study involving a biological disease modifying antirheumatic drug, with spinal pain as the primary endpoint as early…
Abstract Number: 1326 • ACR Convergence 2020
Malignancy Risk Among Patients with Ankylosing Spondylitis in the United States: A Population-Based National Study
Sali Merjanah¹, Mohamad Bittar² and Marina Magrey³, ¹Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, ²The University of Tennessee Health Science Center, Memphis, TN, ³Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Increased cancer risk has been reported with Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), but the correlation is poorly studied in Ankylosing spondylitis…
Abstract Number: 1521 • ACR Convergence 2020
A Novel Gut-joint Migratory TCRab+ Cell Subset Relies on sphingosine-1-phosphate for Tissue Localization
Adam Lefferts¹, Emilie Regner², Eric Norman³, David Claypool⁴, Hannah Schultz⁴, Danielle Sansone-Poe⁴ and Kristine Kuhn⁵, ¹University of Colorado, Anschutz Medical Campus, Aurora, CO, ²University of California San Francisco, San Francisco, CA, ³University of Colorado, Anschutz Medical Campus, Denver, ⁴University of Colorado, Anschutz Medical Campus, Aurora, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Despite findings of similar immune cellular phenotypes in the gut and joint of patients with spondyloarthritis, the mechanistic linkage between intestinal immunology and the…
Abstract Number: 1877 • ACR Convergence 2020
Diagnosis of Axial Spondyloarthritis: A Primary Unmet Educational Need for Rheumatologists Is Interpretation of MRI
Walter Maksymowych¹, Liron Caplan², Atul Deodhar³, Soha Dolatabadi⁴, Mark Hwang⁵, Adam Carlson⁶, Kelly Steed⁷, Amanda Carapellucci⁸, Joel Paschke⁸ and Lianne Gensler⁹, ¹University of Alberta, Edmonton, AB, Canada, ²Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO, ³Oregon Health & Science University, Portland, OR, ⁴Soha Dolatabadi, MD, Los Angeles, CA, ⁵McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ⁶University of Virginia, Charlottesville, VA, ⁷James J. Peters VA Medical Center, Bronx, NY, ⁸CARE Arthritis, Edmonton, AB, Canada, ⁹University of California San Francisco, San Francisco, CA
Background/Purpose: Diagnosis of axial spondyloarthritis (axSpA) is challenging because of absent physical findings in early disease and the limited diagnostic performance of laboratory markers. Considerable…
Abstract Number: 2013 • ACR Convergence 2020
Substantial Lifetime Risk of Developing Ankylosing Spondylitis (Axial Spondyloarthritis) for Relatives. Evidence from a 35-Year Follow-up Family Study of a Swiss Cohort
Sjef van der Linden¹, Peter Villiger², Zhixiu Li³, Matthew Brown⁴, Heinz Baumberger⁵, Hermine Zandwijk⁶ and Muhammad Khan⁷, ¹Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ²Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ³Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ⁴Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ⁵Retired, Flims, Tajikistan, ⁶Retired, Mortroux, Belgium, ⁷Case Western Reserve University, Cleveland OH, Westlake, OH
Background/Purpose: Familial occurrence of ankylosing spondylitis (AS) is well known. Our follow-up study aimed at assessing the incidence of clinically defined AS among first degree…
Abstract Number: 0354 • ACR Convergence 2020
How Do TNF-alpha-Inhibitors in Medical History Affect Patient Reported Outcomes and Retention in Ankylosing Spondylitis Patients Treated with Secukinumab in Real World? – German Observational Study
Uta Kiltz¹, Jan Brandt-Jürgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, ³Ambulantes Rheumazentrum, Erfurt, Germany, ⁴Hannover Medical School, Hannover, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody that selectively inhibits interleukin 17A, is approved for treatment of patients with ankylosing spondylitis (AS). However, there…
Abstract Number: 0904 • ACR Convergence 2020
Response to Ixekizumab by C-reactive Protein Level in Patients with Radiographic Axial Spondyloarthritis: Results from the COAST-V (Biological-Naïve) and COAST-W (TNF Inhibitor-Experienced) Trials at 52 Weeks
John Reveille¹, Proton Rahman², David Sandoval³, Talia Muran³, Andris Kronbergs³, Rebecca Bolce³, Vladimir Geneus³, Theresa Hunter³, Soyi Liu-Leage⁴, Martin Rudwaleit⁵, Jose Maldonado-Cocco⁶ and Filip Van den Bosch⁷, ¹Department of Internal Medicine, University of Texas, Houston, TX, ²Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ³Eli Lilly and Company, Indianapolis, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany, ⁶University of Buenos Aires School of Medicine, Buenos Aires, Argentina, ⁷Ghent University Hospital, Ghent, Belgium
Background/Purpose: Tumor necrosis factor inhibitors (TNFis) are effective treatments for radiographic axial spondyloarthritis (r-axSpA), but may be less effective in patients (pts) without elevated C-reactive…
Abstract Number: 1327 • ACR Convergence 2020
Comorbidity Burden in Patients with Non-Radiographic Axial Spondyloarthritis at Least as High as in Ankylosing Spondylitis
Jonas Sagard¹, Elisabet Lindqvist², Elisabeth Mogard¹, Anna Jöud³, Mats Geijer⁴, Tor Olofsson¹ and Johan K. Wallman¹, ¹Department of Clinical Sciences Lund, Rheumatology, Lund University, Sweden. Department of Rheumatology, Skåne University Hospital, Lund, Sweden., Lund, Sweden, ²Department of Clinical Sciences Lund, Rheumatology, Lund University, Sweden. Department of Rheumatology, Skåne University Hospital. Lund, Sweden, Lund, Sweden, ³Department of Laboratory Medicine, Division of Occupational and Environmental Medicine, Lund University, Sweden., Lund, Sweden, ⁴Department of Radiology, Institute of Clinical Sciences, University of Gothenburg, Sahlgrenska Academy, Gothenburg, Sweden. Department of Radiology, Sahlgrenska University Hospital, Gothenburg, Sweden., Gothenburg, Sweden
Background/Purpose: Few studies have investigated the overall occurrence of comorbidities in patients with non-radiographic axial spondyloarthritis (nr-axSpA) in relation to ankylosing spondylitis (AS). Compared to…
Abstract Number: 1561 • ACR Convergence 2020
Findings Compatible with Axial Spondyloarthritis in Radiologist Reports
Rouhin Sen¹, Emmeline Kim², Evan Manning³, Eric Anderson⁴, Kyle Maier⁵, Elizabeth Cheng⁶ and Liron Caplan⁶, ¹University of Colorado - Division of Rheumatology, Denver, CO, ²University of Colorado School of Medicine, Denver, ³University of Colorado - Department of Medicine, Denver, ⁴Washington University - Division of Rheumatology, St. Louis, ⁵United States Air Force, San Antonio, TX, ⁶Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO
Background/Purpose: The sacroiliac joint (SIJ) has a distinct anatomical shape that can pose challenges to standard planar imaging techniques making the detection of subtle changes…
Abstract Number: 1880 • ACR Convergence 2020
Association of Healthcare Utilization and Costs with Patient-Reported Outcomes in Patients with Ankylosing Spondylitis
Alexis Ogdie¹, Mark Hwang², Phani Veeranki³, Alexandria Portelli³, Steven Sison³, Jason Shafrin³, Sofia Pedro⁴, Esther Yi⁵ and Kaleb Michaud⁶, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³PRECISIONheor, Los Angeles, ⁴FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶FORWARD-The National Data Bank for Rheumatic Diseases; University of Nebraska Medical Center, Wichita
Background/Purpose: Treatments for ankylosing spondylitis (AS) have been shown to improve patient-reported outcome (PRO) measures in clinical studies; however, healthcare decision makers have limited ability…
Abstract Number: 2014 • ACR Convergence 2020
The Relative Diagnostic Utility of Inflammatory Back Pain Criteria in an Inception Cohort of Patients with Psoriasis, Iritis, and Colitis Presenting with Undiagnosed Back Pain
Georg Kröber¹, Ulrich Weber², Raj Carmona³, James Yeung⁴, Jon Chan⁵, Sibel Aydin⁶, Liam Martin⁷, Ariel Masetto⁸, Stephanie Keeling⁹, Olga Ziouzina⁷, Sherry Rohekar¹⁰, Rana Dadashova¹¹, Joel Paschke¹¹, Amanda Carapellucci¹¹, Robert G Lambert¹² and Walter Maksymowych⁹, ¹University of Southern Denmark, Sønderborg, Denmark, ²University of South Denmark, Odense, Denmark, ³St. Joseph's Healthcare, Hamilton, ON, Canada, ⁴James Yeung Rheumatology, Vancouver, BC, Canada, ⁵Artus Health Clinic, Vancouver, BC, Canada, ⁶University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, Ottawa, ON, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Sherbrooke, Sherbrooke, QC, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Lawson Health Research Institute, London, ON, Canada, ¹¹CARE Arthritis, Edmonton, AB, Canada, ¹²University of Alberta and CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: Patients with psoriasis, iritis, or colitis and back pain represent a high-risk population for the presence of axial spondyloarthritis (axSpA). Clinicians rely on the…
Abstract Number: 0358 • ACR Convergence 2020
Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from German Observational Study
Elke Riechers¹, Uta Kiltz², Jan Brandt-Jürgens³, Peter Kästner⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Hannover Medical School, Hannover, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ³Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, ⁴Ambulantes Rheumazentrum, Erfurt, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: There is growing body of evidence that smoking is associated with more active and severe disease in patients (pts) with ankylosing spondylitis (AS)1,2. The…
Abstract Number: 1030 • ACR Convergence 2020
Pain Medication Use Among Ankylosing Spondylitis and Psoriatic Arthritis Patients Before and After Initiation of Biologic Therapy
Theresa Hunter¹, Chi Nguyen², Julie Birt³, Joseph Smith², Mingyang Shan³, Hiangkiat Tan², Jeffrey Lisse³ and Keith Isenberg⁴, ¹Eli Lilly and Company, Indianapolis, ²Healthcore, Inc, Wilmington, DE, ³Eli Lilly and Company, Indianapolis, IN, ⁴Anthem, Inc, Indianapolis, IN
Background/Purpose: Pain is a common symptom among ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients and can be debilitating, making pain management an integral part…
Abstract Number: 1332 • ACR Convergence 2020
Identifying the as Patient at Risk: Is Aortic Root Diameter Associated with HLA-B27?
Milad Baniaamam¹, Sjoerd C. Heslinga², M. Louis Handoko³, Thelma C. Konings³, Otto Kamp³, Vokko P. van Halm⁴, J. Christiaan van Denderen¹, Irene van der Horst-Bruinsma² and Mike Nurmohamed⁵, ¹Reade, Amsterdam, Netherlands, ²Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ³Department of Cardiology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ⁴Department of Cardiology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, ⁵Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands
Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory joint disease (IJD) associated with cardiac involvement particularly aortic valve regurgitation (AVR). AVR in AS is caused by…
Abstract Number: 1618 • ACR Convergence 2020
Frequency and Cost of Repeat HLA-B27 Testing Within the National Capital Consortium over a Calendar Year
Anna Stein¹, Caleb Anderson² and Angelique Collamer³, ¹Walter Reed National Military Medical Center, Takoma Park, MD, ²Walter Reed National Military Medical Center, Bethesda, MD, ³Walter Reed National Military Medical Center, Silver Spring, MD
Background/Purpose: Human leukocyte antigens (HLAs) are proteins encoded for by the major histocompatibility complex located on the short arm of chromosome six. One such allele,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].